<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>Research Support Services</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/64172EBC-9C5B-48AA-8EA8-06FCB117DD9E"><gtr:id>64172EBC-9C5B-48AA-8EA8-06FCB117DD9E</gtr:id><gtr:firstName>Sallie</gtr:firstName><gtr:surname>Lamb</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EABC601B-917B-4973-A947-5641893A00B1"><gtr:id>EABC601B-917B-4973-A947-5641893A00B1</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:otherNames>D</gtr:otherNames><gtr:surname>Perkins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FD52AA0E-162B-48A6-A3D8-73DB58D8566F"><gtr:id>FD52AA0E-162B-48A6-A3D8-73DB58D8566F</gtr:id><gtr:firstName>Fang</gtr:firstName><gtr:surname>Gao</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7836E416-38A8-42C0-8047-9476CFF46437"><gtr:id>7836E416-38A8-42C0-8047-9476CFF46437</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Duncan</gtr:otherNames><gtr:surname>Young</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/01F7D2EE-9712-4AB7-8DE6-C47372B29870"><gtr:id>01F7D2EE-9712-4AB7-8DE6-C47372B29870</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Gates</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A8FB76EB-9207-4C91-A4DD-B32F26A5B8D2"><gtr:id>A8FB76EB-9207-4C91-A4DD-B32F26A5B8D2</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>McCabe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/19595763-E503-4A9D-B0AB-55F2570A8AEC"><gtr:id>19595763-E503-4A9D-B0AB-55F2570A8AEC</gtr:id><gtr:firstName>Vicki</gtr:firstName><gtr:surname>Barber</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700478"><gtr:id>317859E4-D9B5-4BCE-9FA8-9305C38EC190</gtr:id><gtr:title>BALTI 2: The Beta-2 Agonist Lung Injury Trial 2</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700478</gtr:grantReference><gtr:abstractText>Acute Respiratory Distress Syndrome (ARDS) is a common and extremely serious type of respiratory failure among patients in intensive care units. Nearly half of the patients who suffer ARDS die, and many of the survivors have long-term health problems. A small-scale study suggested that intravenous salbutamol given for 7 days early in the course of ARDS may help more patients to survive. This project will determine whether this is correct, by comparing the results among over 1300 patients, half of whom (decided at random) will receive salbutamol and half of whom will receive an inactive solution.</gtr:abstractText><gtr:technicalSummary>BALTI 2 is a multicentre, randomised, double-blind, placebo-controlled trial to determine whether intravenous salbutamol infusion in critically ill adult patients with acute respiratory distress syndrome (ARDS) influences 28 day mortality. The setting will be adult Intensive Care Units (ICUs) within the National Health Service in the UK with the ability to provide full (Level 3) Intensive Care. 

The BALTI 2 trial is an effectiveness study, where the allocation of salbutamol or placebo infusion is determined randomly, but all other treatment decisions are left to the clinicians managing the patient. 1344 patients will be randomised within 72 hours of the onset of ARDS, and and the primary outcome is mortality 28 days after randomisation. All patients will be followed up at 1 year to determine whether salbutamol treatment has any effect on the health of survivors over the subsequent year. An economic evaluation willl be conducted alongside the trial.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-12-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1965152</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Clinical Research Network (CRN)</gtr:department><gtr:description>IMPACT Study</gtr:description><gtr:id>21B62C4F-8FE1-4AFB-AF60-16070D6D5984</gtr:id><gtr:impact>1. to raise awareness in the UK critical care community on impact of clinical research;
2. to evaluate the outputs and outcomes of the UK Intensive Care Foundation funded clinical trials.</gtr:impact><gtr:outcomeId>58b816ec222107.45849994-1</gtr:outcomeId><gtr:partnerContribution>Professor Paul Dark, Chair of the NIHR Critical Care CRN, supported the idea, contributed to the protocol and supported to obtain a CRN funding &amp;pound;5000 for the study,</gtr:partnerContribution><gtr:piContribution>I had the original idea on evaluating IMPACT of UK critical care RCTs which was accepted by the Intensive Care Foundation and NIHR CRN for Critical Care specialty. Dr Jaimin Patel, Clinician Scientist, University of Birmingham (from my team) under my and Dr Paul Dark (Prof in University of Manchester) supervision leads this prospective national evaluation of impact of these RCTs (including Balti-2) on changes of clinical practice.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>29th and 30th Internaitonal Symposium of Intensive Care and Emegency Medicine, Brussels, Belgium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>72C37033-4B8F-4141-834E-AF4A17A15372</gtr:id><gtr:impact>More than thousands participants attended symposium each year to take in newly released clinical research information.</gtr:impact><gtr:outcomeId>56cb3518eab733.83755206</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ccforum.com/supplements/all</gtr:url><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>?	16th World Congress of Anaesthesiology, Hong Kong</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CC88F77B-7E51-48E6-860C-DA0EC03084DD</gtr:id><gtr:impact>Should we be using beta agonists in ARDS?</gtr:impact><gtr:outcomeId>58b822b844e649.32662250</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://wca2016.com/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>12th Annual Critical Care Symposium, April 2015, Manchester England</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D62B3343-E179-4901-9ADC-2990169713D9</gtr:id><gtr:impact>The faculties of the Symposiums are from the best researchers and the best policy makers in critical care communities, and it was great honour to be a part of it. More than 500 participants from all over the world attended this annual event for the purpose of receiving the most updated research information on use of beta-agonists in ARDS patients which sparked questions and debates.</gtr:impact><gtr:outcomeId>58b80177ccb121.16789147</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://critcaresymposium.co.uk/site3/</gtr:url><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>?	International Clinical Trial Conference July 2015, Orlando, Florida, USA</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4C68C433-910B-4344-9DCB-8C4F4F921C8B</gtr:id><gtr:impact>Exchanged experience in how to handle a premature terminated clinical trial.</gtr:impact><gtr:outcomeId>58b823c07808f0.48427094</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://clinicaltrials.conferenceseries.com/2015</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Intensive Care Society UK State of Art Conference 2011, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D2129945-BF91-4C66-B5E0-01B797729B9F</gtr:id><gtr:impact>Approximately 500 participants attended the Conference to take in the BALTI-2 findings prior to the publication, which stimulated loads of questions and discussions amongst the community.</gtr:impact><gtr:outcomeId>56cb326d341289.56986500</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ics.ac.uk/ics-homepage/events/past-meetings/state-of-the-art-meeting-2011/</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>dissemination to participants</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3CCDCB4A-A8C3-4D88-874B-D02880664118</gtr:id><gtr:impact>Surviving participants informed of publication of the trial's results by post.

None yet.</gtr:impact><gtr:outcomeId>ReWHw4zuv3x</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Trial of drug for acute respiratory distress syndrome stopped following increased mortality and no improvement in outcomes (BALTI-2 study)-Press Release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BDBBC675-5DEB-4CEB-A774-A001302AC7AF</gtr:id><gtr:impact>Intensive Care community in the world received the Release, which stimulated questions and discussions afterwards, and the Society applied the evidence into the Guideline to change ICM clinicians practice.</gtr:impact><gtr:outcomeId>56cb2c4f0b6759.68311358</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61623-1/abstract</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>a feasibility study for BALTI II</gtr:description><gtr:end>2007-01-02</gtr:end><gtr:fundingOrg>Intensive Care Foundation (ICF)</gtr:fundingOrg><gtr:id>11B05F77-63B0-45F3-B176-9B07816D85ED</gtr:id><gtr:outcomeId>56cb2de7f30c39.49334498</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>178000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BALTI II treatment costs subvention</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Department of Health (DH)</gtr:fundingOrg><gtr:id>DFEE35B1-7DB8-466C-B2E3-70B6D435B5C9</gtr:id><gtr:outcomeId>56cb15b42b1032.27522202</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>248983</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Research for Patient Benefit</gtr:department><gtr:description>The Beta Agonist Lung Injury Trial (prevention) : BALTI-prevention study</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>PB-PG-0408-16104</gtr:fundingRef><gtr:id>F312E7A4-B083-4DB2-8A65-02BF054DC4F8</gtr:id><gtr:outcomeId>56cb1df470cd06.63148754</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Our findings of Balti-2 trial provided the good evidence for revised International Guideline for Sepsis Management 2017</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016</gtr:guidelineTitle><gtr:id>A47B1479-FFAB-4737-8B02-7B8EFE510B6D</gtr:id><gtr:impact>provided the scientific evidence for the guideline update.</gtr:impact><gtr:outcomeId>58b82b52e014c2.57668644</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.survivingsepsis.org/Guidelines/Pages/default.aspx</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Change the International Surviving Sepsis Campgain Guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>The International Surviving Sepsis Campaign Guidelines for management of severe sepsis and septic shock 2012</gtr:guidelineTitle><gtr:id>C237823C-8A42-4BE0-94DA-02905BA2261C</gtr:id><gtr:impact>Salbutamol infusion resulted in a 10.8% increase in 28-day mortality, which means that every 9 ARDS patients treated with salbutamol would result in one extra death. Consistent with 28-day mortality, there was a 8.4% increase in ICU mortality and 6% increase in hospital mortality in the salbutamol arm although this did not reach statistical significance. Again consistent with mortality data, salbutamol group had the mean 2.68 day reduction in ventilator-free days, and the mean 2.3 organ free days compared with the placebo arm. ARDS survivors in salbutamol group required average 3.4 more days in ICU than placebo arm and this nearly reached a statistical significance. We did not find a significant difference between two groups in length of ICU and hospital stay, in level 3 care bed days. The data suggested that quality of life was lower in the salbutamol group. Health economic analyses showed that costs of care were slightly higher in the salbutamol group and that
salbutamol was unlikely to be cost-effective.
However, our snapshot audit in 2013 showed beta-2 agonists were still used as one of drug treatments for ARDS: 8% in the UK and 14% in China patients with ARDS.</gtr:impact><gtr:outcomeId>56e012a61cc548.42468865</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://inc.sagepub.com/content/14/3/196.full.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in Editorial, Lancet with the publication on our trial.</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>AD9BEBA6-72A3-4704-A237-7623A90FDC69</gtr:id><gtr:impact>International practice on use of Beta-2 agonists in critically ill patients.</gtr:impact><gtr:outcomeId>NurQRhqzKS1</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/22166901</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>EF16913E-E19B-413D-B763-95C9C63A04C9</gtr:id><gtr:title>The rise and fall of ?-agonists in the treatment of ARDS.</gtr:title><gtr:parentPublicationTitle>Critical care (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/502b10a2a051c52675b64b47eb723683"><gtr:id>502b10a2a051c52675b64b47eb723683</gtr:id><gtr:otherNames>Bassford CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1364-8535</gtr:issn><gtr:outcomeId>56cb24ac7c3554.54388189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A1FB573-2318-4B51-BCE8-9F7C1B0DDBC2</gtr:id><gtr:title>The Beta Agonist Lung Injury TrIal (BALTI)--prevention trial protocol.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/746bb30afe66da438f82826eb311c7bd"><gtr:id>746bb30afe66da438f82826eb311c7bd</gtr:id><gtr:otherNames>Perkins GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56cb1a1d9d28d3.36825363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C610270-03BF-4E84-8AD9-964C1265ED91</gtr:id><gtr:title>The Use of Beta 2-Agonists for the Treatment of Acute Respiratory Distress Syndrome</gtr:title><gtr:parentPublicationTitle>Journal of the Intensive Care Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/371f02c51e7d9de90346b0560fdbd6aa"><gtr:id>371f02c51e7d9de90346b0560fdbd6aa</gtr:id><gtr:otherNames>Howes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56cb10c77b7342.95260748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB0FCF1F-A1AA-401D-9471-82B9336075D1</gtr:id><gtr:title>Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/746bb30afe66da438f82826eb311c7bd"><gtr:id>746bb30afe66da438f82826eb311c7bd</gtr:id><gtr:otherNames>Perkins GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56cb18408c0fa7.28170208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9833164-5F11-4893-A8AF-E35925C382FA</gtr:id><gtr:title>Effect of intravenous ?-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63dc850f1251dfb53352eadcbb733f27"><gtr:id>63dc850f1251dfb53352eadcbb733f27</gtr:id><gtr:otherNames>Gao Smith F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>fXWYwSrZPUD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA01B6A7-9CB8-4F89-92B6-DD39DA74449B</gtr:id><gtr:title>The beta agonist lung injury trial prevention. A randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/746bb30afe66da438f82826eb311c7bd"><gtr:id>746bb30afe66da438f82826eb311c7bd</gtr:id><gtr:otherNames>Perkins GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56cb195d5698c9.73447992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C68B16B-6D43-4DEA-8594-FDADBD9C3244</gtr:id><gtr:title>Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09f8a600f7796e05a154fa68ca36241f"><gtr:id>09f8a600f7796e05a154fa68ca36241f</gtr:id><gtr:otherNames>Gates S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>b8uiAkzJLgF</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700478</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>